拉斯的SI/II口袋:一个曾经"无毒"的目标的机会
Tanos C C França1,2,3, Michael Maddalena4,5, Imène Kouidmi4,5
1INRS Centre Armand Frappier Santé Biotechnologie, 531 des Prairies Boulevard, Laval, Quebec H7 V 1B7, Canada.
ACS omega
|March 17, 2025
概括
拉斯突变驱动癌症,但SI / II口袋提供了一个新的治疗目标. 这个口袋在GTP结合状态下是可访问的,这表明它是新型Ras抑制剂的有希望的位置.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 拉斯GTPases是关键的致癌驱动因素,特别是HRas在头癌和泌尿生殖系统癌症中.
- 以前无法治疗的Ras家族现在呈现出一个潜在的目标:在SOS1结合部位附近保存的SI/II口袋.
研究的目的:
- 在GDP-bound HRasG12V.V中描述SI/II口袋的拓.
- 在不同HRas状态下调查SI/II口袋的结构动态.
主要方法:
- 产生了本地GDP-bound HRasG12V.的晶体结构.
- 在原生和合成HRas模型上利用分子动力学模拟.
- 分析了GDP-bound和GppNHp-bound HRasG12V. 的结构.
主要成果:
- 在本土GDP受约束的HR中,SI/II口袋是无法进入的.
- 在GppNHp结合状态下,可以进入该口袋,特别是在突变的HRas中.
- α2螺旋和残留物Y71通过"tyrosine toggle"机制控制口袋的可访问性.
结论:
- HRas的GTP结合状态是SI/II口袋导向Ras抑制剂最有希望的目标.
- 了解SI / II口袋的动态对于开发泛种族药物至关重要.
相关概念视频
Structure-Activity Relationships and Drug Design
474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K


